Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pulse BiosciencesPLSE -2.60%31 Cash-to-Debt is 15.01 as of Jun. 2026, which is 63% above its 10-year median of 9.20. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Pulse Biosciences ranks better than 78.98% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pulse Biosciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 15.01.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pulse Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Pulse Biosciences's Cash-to-Debt or its related term are showing as below:
PLSE'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72 Med: 9.2 Max: No Debt
Current: 15.01
During the past 12 years, Pulse Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.72. And the median was 9.20.
PLSE's Cash-to-Debt is ranked better than 78.98% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs PLSE: 15.01
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Pulse Biosciences Cash-to-Debt Related Terms
Pulse Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Pulse Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences (PLSE) has a Cash-to-Debt of 15.01 as of Jun. 2026. This is 63% above median its historical median of 9.20. Over the past decade, Pulse Biosciences' Cash-to-Debt has ranged from 0.72 to 10,000.00. According to the industry distribution chart, Pulse Biosciences ranks #177 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is Pulse Biosciences' Cash-to-Debt too high?
Pulse Biosciences' current Cash-to-Debt of 15.01 is 63% above median its 10-year median of 9.20. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.61. Pulse Biosciences' value of 15.01 is 832.3% above this industry median. Based on the distribution chart, Pulse Biosciences ranks #177 out of 842 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' Cash-to-Debt compare to WRBY and ATRC?
According to the Medical Devices & Instruments industry distribution chart, Pulse Biosciences ranks #177 out of 842 companies for Cash-to-Debt. This places Pulse Biosciences in the top 21% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.61. Pulse Biosciences' value of 15.01 is 832.3% above this benchmark. Historically, Pulse Biosciences' own Cash-to-Debt has ranged from 0.72 to 10,000.00 over the past decade. While the company's 10-year median is 9.20 vs. the industry median of 1.61, Pulse Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.61, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulse Biosciences's current Cash-to-Debt of 15.01 is 832.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulse Biosciences's current Cash-to-Debt is 15.01, which is 63% above median its own 10-year median of 9.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current Cash-to-Debt of 15.01. The current Cash-to-Debt is 15.01, which is 63% above median its 10-year median of 9.20 and 832.3% above the Medical Devices & Instruments industry median of 1.61. Pulse Biosciences' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current Cash-to-Debt is 15.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score
Get the complete analysis for PLSE
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSE has been successfully added to your 
